BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morena M, Jaussent I, Dupuy AM, Bargnoux AS, Kuster N, Chenine L, Leray-Moragues H, Klouche K, Vernhet H, Canaud B. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant. 2015;30:1345-1356. [PMID: 25854266 DOI: 10.1093/ndt/gfv081] [Cited by in Crossref: 63] [Cited by in F6Publishing: 70] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Xiao Q, Tang Y, Luo H, Chen S, Chen R, Yan Z, Pu L, Wang L, Li G, Li Y. Sclerostin is involved in osteogenic transdifferentiation of vascular smooth muscle cells in chronic kidney disease-associated vascular calcification with non-canonical Wnt signaling. Ren Fail 2022;44:1426-42. [PMID: 36017689 DOI: 10.1080/0886022X.2022.2114370] [Reference Citation Analysis]
2 Dincel AS, Jørgensen NR; IOF-IFCC Joint Committee on Bone Metabolism (C-BM). New Emerging Biomarkers for Bone Disease: Sclerostin and Dickkopf-1 (DKK1). Calcif Tissue Int 2022. [PMID: 36165920 DOI: 10.1007/s00223-022-01020-9] [Reference Citation Analysis]
3 Priyadarshini G, Rajappa M. PREDICTIVE MARKERS IN CHRONIC KIDNEY DISEASE. Clin Chim Acta 2022:S0009-8981(22)01275-X. [PMID: 35995274 DOI: 10.1016/j.cca.2022.08.018] [Reference Citation Analysis]
4 Romejko K, Rymarz A, Szamotulska K, Bartoszewicz Z, Niemczyk S. Serum Osteoprotegerin Is an Independent Marker of Left Ventricular Hypertrophy, Systolic and Diastolic Dysfunction of the Left Ventricle and the Presence of Pericardial Fluid in Chronic Kidney Disease Patients. Nutrients 2022;14:2893. [DOI: 10.3390/nu14142893] [Reference Citation Analysis]
5 Golledge J, Thanigaimani S. Role of Sclerostin in Cardiovascular Disease. Arterioscler Thromb Vasc Biol 2022;42:e187-202. [PMID: 35546488 DOI: 10.1161/ATVBAHA.122.317635] [Reference Citation Analysis]
6 Okasha KM, Aboufreikha MH, Elrefaey W, Ashmawy MM, Mourad H, Elsebaey MA, Elnaggar MH, Mashaal RG, Metwally S, Mashal SSA, Shalaby NA, Elhoseny SA, Alkassas A, Elbarbary M, Shoeib O, Ali DA, Baiomy N, Alnabawy SM. Association of Serum Osteoprotegerin Level With Myocardial Injury and Cardiovascular Calcification in Chronic Kidney Disease Patients. Front Med 2022;9:814970. [DOI: 10.3389/fmed.2022.814970] [Reference Citation Analysis]
7 Ren SC, Mao N, Yi S, Ma X, Zou JQ, Tang X, Fan JM. Vascular Calcification in Chronic Kidney Disease: An Update and Perspective. Aging Dis 2022;13:673-97. [PMID: 35656113 DOI: 10.14336/AD.2021.1024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Omran A, Atanasova D, Landgren F, Magnusson P. Sclerostin: From Molecule to Clinical Biomarker. Int J Mol Sci 2022;23:4751. [PMID: 35563144 DOI: 10.3390/ijms23094751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Roumeliotis S, Duni A, Vaios V, Kitsos A, Liakopoulos V, Dounousi E. Vitamin K Supplementation for Prevention of Vascular Calcification in Chronic Kidney Disease Patients: Are We There Yet? Nutrients 2022;14:925. [PMID: 35267901 DOI: 10.3390/nu14050925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Mace ML, Egstrand S, Morevati M, Olgaard K, Lewin E. New Insights to the Crosstalk between Vascular and Bone Tissue in Chronic Kidney Disease-Mineral and Bone Disorder. Metabolites 2021;11:849. [PMID: 34940607 DOI: 10.3390/metabo11120849] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kim JS, Hwang HS. Vascular Calcification in Chronic Kidney Disease: Distinct Features of Pathogenesis and Clinical Implication. Korean Circ J 2021;51:961-82. [PMID: 34854578 DOI: 10.4070/kcj.2021.0995] [Reference Citation Analysis]
12 Neto R, Pereira L, Magalhães J, Quelhas-Santos J, Martins S, Carvalho C, Frazão JM. Sclerostin and DKK1 circulating levels associate with low bone turnover in patients with chronic kidney disease Stages 3 and 4. Clin Kidney J 2021;14:2401-8. [PMID: 34754436 DOI: 10.1093/ckj/sfab081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Neto R, Pereira L, Magalhães J, Quelhas-Santos J, Frazão J. Low bone turnover is associated with plain X-ray vascular calcification in predialysis patients. PLoS One 2021;16:e0258284. [PMID: 34644326 DOI: 10.1371/journal.pone.0258284] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Al-Hakeim HK, Asad HN, Maes M. Wnt/β-catenin pathway proteins in end-stage renal disease. Biomark Med 2021;15:1423-34. [PMID: 34554011 DOI: 10.2217/bmm-2021-0177] [Reference Citation Analysis]
15 Fehérvári L, Frigy A, Kocsis L, Szabó IA, Szabo TM, Urkon M, Jakó Z, Nagy EE. Serum Osteoprotegerin and Carotid Intima-Media Thickness Are Related to High Arterial Stiffness in Heart Failure with Reduced Ejection Fraction. Diagnostics (Basel) 2021;11:764. [PMID: 33923139 DOI: 10.3390/diagnostics11050764] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage-Proust MH, Prieto-Alhambra D, Torres PU, Cannata-Andia J; European Renal Osteodystrophy (EUROD) workgroup, an initiative of the CKD-MBD working group of the ERA-EDTA, and the committee of Scientific Advisors and National Societies of the IOF. European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dial Transplant 2021;36:42-59. [PMID: 33098421 DOI: 10.1093/ndt/gfaa192] [Cited by in Crossref: 22] [Cited by in F6Publishing: 31] [Article Influence: 22.0] [Reference Citation Analysis]
17 Kern A, Stompór T, Kiewisz J, Kraziński BE, Kiezun J, Kiezun M, Górny J, Sienkiewicz E, Gromadziński L, Onichimowski D, Bil J. The Impact of Sclerostin Levels on Long-Term Prognosis in Patients Undergoing Coronary Angiography: A Personalized Approach with 9-Year Follow-Up. J Pers Med 2021;11:186. [PMID: 33800939 DOI: 10.3390/jpm11030186] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Zou Y, Yang M, Wang J, Cui L, Jiang Z, Ding J, Li M, Zhou H. Association of sclerostin with cardiovascular events and mortality in dialysis patients. Ren Fail 2020;42:282-8. [PMID: 32216514 DOI: 10.1080/0886022X.2020.1741386] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
19 Forster CM, White CA, Turner ME, Norman PA, Ward EC, Hopman WM, Adams MA, Holden RM. Circulating Levels of Dickkopf-Related Protein 1 Decrease as Measured GFR Declines and Are Associated with PTH Levels. Am J Nephrol 2020;51:871-80. [PMID: 33238271 DOI: 10.1159/000511658] [Reference Citation Analysis]
20 Guven S, Gokce I, Cicek N, Yaman A, Vatansever P, Alpay H. Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children. J Pediatr Endocrinol Metab 2020;33:1383-90. [PMID: 33068383 DOI: 10.1515/jpem-2020-0140] [Reference Citation Analysis]
21 Hildebrand S, Cunningham J. Is there a role for bisphosphonates in vascular calcification in chronic kidney disease? Bone 2021;142:115751. [PMID: 33188959 DOI: 10.1016/j.bone.2020.115751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
22 Salam S, Gallagher O, Gossiel F, Paggiosi M, Eastell R, Khwaja A. Vascular calcification relationship to vascular biomarkers and bone metabolism in advanced chronic kidney disease. Bone 2021;143:115699. [PMID: 33091638 DOI: 10.1016/j.bone.2020.115699] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
23 Kitaura H, Marahleh A, Ohori F, Noguchi T, Shen WR, Qi J, Nara Y, Pramusita A, Kinjo R, Mizoguchi I. Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption. Int J Mol Sci 2020;21:E5169. [PMID: 32708317 DOI: 10.3390/ijms21145169] [Cited by in Crossref: 19] [Cited by in F6Publishing: 56] [Article Influence: 9.5] [Reference Citation Analysis]
24 Pathak JL, Bravenboer N, Klein-Nulend J. The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases. Front Endocrinol (Lausanne) 2020;11:405. [PMID: 32733380 DOI: 10.3389/fendo.2020.00405] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
25 Lin X, Onda DA, Yang CH, Lewis JR, Levinger I, Loh K. Roles of bone-derived hormones in type 2 diabetes and cardiovascular pathophysiology. Mol Metab 2020;40:101040. [PMID: 32544571 DOI: 10.1016/j.molmet.2020.101040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
26 Zhao B, Chen A, Wang H, Cui J, Sun Y, Xu L, Mao Y. The relationship between sclerostin and carotid artery atherosclerosis in patients with stage 3-5 chronic kidney disease. Int Urol Nephrol 2020;52:1329-36. [PMID: 32458213 DOI: 10.1007/s11255-020-02495-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Pereira L, Frazão JM. The bone-vessel axis in chronic kidney disease: An update on biochemical players and its future role in laboratory medicine. Clin Chim Acta 2020;508:221-7. [PMID: 32422129 DOI: 10.1016/j.cca.2020.05.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
28 Maré A, D'Haese PC, Verhulst A. The Role of Sclerostin in Bone and Ectopic Calcification. Int J Mol Sci 2020;21:E3199. [PMID: 32366042 DOI: 10.3390/ijms21093199] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
29 Rroji M, Figurek A, Spasovski G. Should We Consider the Cardiovascular System While Evaluating CKD-MBD? Toxins (Basel) 2020;12:E140. [PMID: 32106499 DOI: 10.3390/toxins12030140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
30 Wu CF, Hou JS, Wang CH, Lin YL, Lai YH, Kuo CH, Liou HH, Tsai JP, Hsu BG. Serum Sclerostin But Not DKK-1 Correlated with Central Arterial Stiffness in End Stage Renal Disease Patients. Int J Environ Res Public Health 2020;17:E1230. [PMID: 32075016 DOI: 10.3390/ijerph17041230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
31 Bouquegneau A, Evenepoel P, Paquot F, Malaise O, Cavalier E, Delanaye P. Sclerostin within the chronic kidney disease spectrum. Clin Chim Acta 2020;502:84-90. [PMID: 31866333 DOI: 10.1016/j.cca.2019.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
32 Dai L, Debowska M, Lukaszuk T, Bobrowski L, Barany P, Söderberg M, Thiagarajan D, Frostegård J, Wennberg L, Lindholm B, Qureshi AR, Waniewski J, Stenvinkel P. Phenotypic features of vascular calcification in chronic kidney disease. J Intern Med 2020;287:422-34. [PMID: 31823455 DOI: 10.1111/joim.13012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
33 Tschiderer L, Klingenschmid G, Nagrani R, Willeit J, Laukkanen JA, Schett G, Kiechl S, Willeit P. Osteoprotegerin and Cardiovascular Events in High-Risk Populations: Meta-Analysis of 19 Prospective Studies Involving 27 450 Participants. J Am Heart Assoc 2018;7:e009012. [PMID: 30369329 DOI: 10.1161/JAHA.118.009012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
34 Evenepoel P, Opdebeeck B, David K, D'Haese PC. Bone-Vascular Axis in Chronic Kidney Disease. Adv Chronic Kidney Dis 2019;26:472-83. [PMID: 31831125 DOI: 10.1053/j.ackd.2019.09.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
35 Chen B, Zhao Y, Han D, Zhao B, Mao Y, Cui ZK, Chu YC, Feng L, Yin S, Wang CY, Wang X, Xu MJ, Zhao G. Wnt1 inhibits vascular smooth muscle cell calcification by promoting ANKH expression. J Mol Cell Cardiol 2019;135:10-21. [PMID: 31356809 DOI: 10.1016/j.yjmcc.2019.07.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
36 Kalousová M, Dusilová-Sulková S, Kuběna AA, Zakiyanov O, Tesař V, Zima T. Sclerostin levels predict cardiovascular mortality in long-term hemodialysis patients: A prospective observational cohort study. Physiol Res 2019;68:547-58. [PMID: 31177791 DOI: 10.33549/physiolres.934034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
37 Moghazy TF, Zaki MA, Kandil NS, Maharem DA, Matrawy KA, Zaki MA, El-banna AMI. Serum sclerostin as a potential biomarker of vascular and valvular types of calcification in chronic kidney disease cases with and without maintenance hemodialysis. Alexandria Journal of Medicine 2019;55:15-24. [DOI: 10.1080/20905068.2019.1592930] [Reference Citation Analysis]
38 Zhou M, Li S, Pathak JL. Pro-inflammatory Cytokines and Osteocytes. Curr Osteoporos Rep 2019;17:97-104. [DOI: 10.1007/s11914-019-00507-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
39 Yang HY, Wu DA, Chen MC, Hsu BG. Correlation between sclerostin and Dickkopf-1 with aortic arterial stiffness in patients with type 2 diabetes: A prospective, cross-sectional study. Diab Vasc Dis Res 2019;16:281-8. [PMID: 30547685 DOI: 10.1177/1479164118816661] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
40 Chae SY, Chung W, Kim YH, Oh YK, Lee J, Choi KH, Ahn C, Kim YS. The Correlation of Serum Osteoprotegerin with Non-Traditional Cardiovascular Risk Factors and Arterial Stiffness in Patients with Pre-Dialysis Chronic Kidney Disease: Results from the KNOW-CKD Study. J Korean Med Sci 2018;33:e322. [PMID: 30595681 DOI: 10.3346/jkms.2018.33.e322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
41 Li M, Zhou H, Yang M, Xing C. Relationship between serum sclerostin, vascular sclerostin expression and vascular calcification assessed by different methods in ESRD patients eligible for renal transplantation: a cross-sectional study. Int Urol Nephrol 2019;51:311-23. [PMID: 30515734 DOI: 10.1007/s11255-018-2033-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
42 Chang YC, Hsu BG, Liou HH, Lee CJ, Wang JH. Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients. BMC Cardiovasc Disord 2018;18:214. [PMID: 30482161 DOI: 10.1186/s12872-018-0955-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
43 Reiss AB, Miyawaki N, Moon J, Kasselman LJ, Voloshyna I, D'avino R, De Leon J. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies. Atherosclerosis 2018;278:49-59. [DOI: 10.1016/j.atherosclerosis.2018.08.046] [Cited by in Crossref: 53] [Cited by in F6Publishing: 75] [Article Influence: 13.3] [Reference Citation Analysis]
44 Li ZJ, Du LF, Qin Y, Liu JB, Luo XH. Ultrasound Assessment of Intima-media Thickness and Diameter of Carotid Arteries in Patients Undergoing Hemodialysis or Renal Transplantation. Curr Med Sci 2018;38:727-33. [PMID: 30128885 DOI: 10.1007/s11596-018-1937-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Figurek A, Spasovski G. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder? Int Urol Nephrol 2018;50:1863-70. [PMID: 30030677 DOI: 10.1007/s11255-018-1935-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
46 Krzanowski M, Krzanowska K, Dumnicka P, Gajda M, Woziwodzka K, Fedak D, Grodzicki T, Litwin JA, Sułowicz W. Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification. Ther Apher Dial 2018;22:519-29. [PMID: 29974642 DOI: 10.1111/1744-9987.12681] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
47 Novo-Rodríguez C, García-Fontana B, Luna-Del Castillo JD, Andújar-Vera F, Ávila-Rubio V, García-Fontana C, Morales-Santana S, Rozas-Moreno P, Muñoz-Torres M. Circulating levels of sclerostin are associated with cardiovascular mortality. PLoS One 2018;13:e0199504. [PMID: 29928063 DOI: 10.1371/journal.pone.0199504] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
48 Vlot MC, den Heijer M, de Jongh RT, Vervloet MG, Lems WF, de Jonge R, Obermayer-Pietsch B, Heijboer AC. Clinical utility of bone markers in various diseases. Bone 2018;114:215-25. [PMID: 29920402 DOI: 10.1016/j.bone.2018.06.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
49 Özkalaycı F, Gülmez Ö, Uğur-Altun B, Pandi-Perumal SR, Altun A. The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox. Balkan Med J 2018;35:225-32. [PMID: 29687784 DOI: 10.4274/balkanmedj.2018.0579] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
50 Bisson SK, Ung RV, Mac-Way F. Role of the Wnt/β-Catenin Pathway in Renal Osteodystrophy. Int J Endocrinol 2018;2018:5893514. [PMID: 29808090 DOI: 10.1155/2018/5893514] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
51 Lips L, de Roij van Zuijdewijn CLM, Ter Wee PM, Bots ML, Blankestijn PJ, van den Dorpel MA, Fouque D, de Jongh R, Pelletier S, Vervloet MG, Nubé MJ, Grooteman MPC. Serum sclerostin: relation with mortality and impact of hemodiafiltration. Nephrol Dial Transplant 2017;32:1217-23. [PMID: 27342581 DOI: 10.1093/ndt/gfw246] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
52 Zwakenberg SR, van der Schouw YT, Schalkwijk CG, Spijkerman AMW, Beulens JWJ. Bone markers and cardiovascular risk in type 2 diabetes patients. Cardiovasc Diabetol 2018;17:45. [PMID: 29571288 DOI: 10.1186/s12933-018-0691-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
53 Tan SJ, Cai MM. Is there a role for newer biomarkers in chronic kidney disease-mineral and bone disorder management? Nephrology (Carlton) 2017;22 Suppl 2:14-8. [PMID: 28429560 DOI: 10.1111/nep.13015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
54 Gong L, Zheng D, Yuan J, Cao L, Ni Z, Fang W. Elevated levels of serum sclerostin are linked to adverse cardiovascular outcomes in peritoneal dialysis patients. Int Urol Nephrol 2018;50:955-61. [PMID: 29356934 DOI: 10.1007/s11255-018-1795-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
55 Zeng C, Guo C, Cai J, Tang C, Dong Z. Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease. Diabetes and Vascular Disease Research 2018;15:99-105. [DOI: 10.1177/1479164117742316] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
56 Delanaye P, Paquot F, Bouquegneau A, Blocki F, Krzesinski J, Evenepoel P, Pottel H, Cavalier E. Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know. Nephrology Dialysis Transplantation 2018;33:1404-10. [DOI: 10.1093/ndt/gfx282] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
57 Avila M, Mora C, Prado MDC, Zavala M, Paniagua R; Mexican Collaborative Group. Osteoprotegerin Is the Strongest Predictor for Progression of Arterial Calcification in Peritoneal Dialysis Patients. Am J Nephrol 2017;46:39-46. [PMID: 28614819 DOI: 10.1159/000477380] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
58 Gungor O, Kocyigit I, Yilmaz MI, Sezer S. Role of vascular calcification inhibitors in preventing vascular dysfunction and mortality in hemodialysis patients. Semin Dial 2018;31:72-81. [DOI: 10.1111/sdi.12616] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
59 Carlson N, Mortensen OH, Axelsen M, Pedersen RS, Heaf JG. Clearance of Sclerostin, Osteocalcin, Fibroblast Growth Factor 23, and Osteoprotegerin by Dialysis. Blood Purif 2017;44:122-8. [PMID: 28554171 DOI: 10.1159/000465513] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
60 Zhou H, Yang M, Li M, Cui L. Radial artery sclerostin expression in chronic kidney disease stage 5 predialysis patients: a cross-sectional observational study. Int Urol Nephrol 2017;49:1433-7. [PMID: 28455660 DOI: 10.1007/s11255-017-1604-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
61 Znorko B, Oksztulska-Kolanek E, Michałowska M, Kamiński T, Pawlak K. Does the OPG/RANKL system contribute to the bone-vascular axis in chronic kidney disease? A systematic review. Adv Med Sci 2017;62:52-64. [PMID: 28189120 DOI: 10.1016/j.advms.2016.08.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
62 Drüeke TB, Massy ZA. Changing bone patterns with progression of chronic kidney disease. Kidney Int 2016;89:289-302. [PMID: 26806832 DOI: 10.1016/j.kint.2015.12.004] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 16.4] [Reference Citation Analysis]
63 Hsu BG, Liou HH, Lee CJ, Chen YC, Ho GJ, Lee MC. Serum Sclerostin as an Independent Marker of Peripheral Arterial Stiffness in Renal Transplantation Recipients: A Cross-Sectional Study. Medicine (Baltimore) 2016;95:e3300. [PMID: 27082570 DOI: 10.1097/MD.0000000000003300] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
64 Kanbay M, Solak Y, Siriopol D, Aslan G, Afsar B, Yazici D, Covic A. Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int Urol Nephrol 2016;48:2029-42. [DOI: 10.1007/s11255-016-1387-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
65 Lv W, Guan L, Zhang Y, Yu S, Cao B, Ji Y. Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4. Int Urol Nephrol 2016;48:2043-50. [DOI: 10.1007/s11255-016-1379-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
66 Seifert ME, Hruska KA. The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder. Transplantation 2016;100:497-505. [PMID: 26356179 DOI: 10.1097/TP.0000000000000903] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
67 Almroth G, Lönn J, Uhlin F, Brudin L, Andersson B, Hahn-Zoric M. Sclerostin, TNF-alpha and Interleukin-18 Correlate and are Together with Klotho Related to Other Growth Factors and Cytokines in Haemodialysis Patients. Scand J Immunol 2016;83:58-63. [PMID: 26448366 DOI: 10.1111/sji.12392] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
68 Dekker M, Pasch A, van der Sande F, Konings C, Bachtler M, Dionisi M, Meier M, Kooman J, Canaud B. High-Flux Hemodialysis and High-Volume Hemodiafiltration Improve Serum Calcification Propensity. PLoS One 2016;11:e0151508. [PMID: 27064679 DOI: 10.1371/journal.pone.0151508] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
69 Demir P, Erdenen F, Aral H, Emre T, Kose S, Altunoglu E, Dolgun A, Inal BB, Turkmen A. Serum Osteoprotegerin Levels Related With Cardiovascular Risk Factors in Chronic Kidney Disease. J Clin Lab Anal 2016;30:811-7. [PMID: 26991325 DOI: 10.1002/jcla.21941] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
70 Gluba-Brzózka A, Michalska-Kasiczak M, Franczyk B, Nocuń M, Toth P, Banach M, Rysz J. Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. Lipids Health Dis 2016;15:22. [PMID: 26843213 DOI: 10.1186/s12944-016-0191-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
71 Spartalis M, Papagianni A. Receptor activator of nuclear factor κB ligand/osteoprotegerin axis and vascular calcifications in patients with chronic kidney disease. World J Nephrol 2016; 5(1): 1-5 [PMID: 26788459 DOI: 10.5527/wjn.v5.i1.1] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]